Eric J. Sherman, MD, on the Efficacy of Cabozantinib in Refractory Differentiated Thyroid Cancer

Video

Eric J. Sherman, MD, examines the phase 3 COSMIC-311 trial with cabozantinib in radioiodine-refractory differentiated thyroid cancer.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® sat down with Eric J. Sherman, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, to discuss the efficacy of the tyrosine kinase inhibitor (TKI) cabozantinib (Cabometyx) in radioiodine-refractory differentiated thyroid cancer, as seen in the phase 3 COSMIC-311 trial (NCT03690388). Data from the trial revealed that cabozantinib yielded a notable benefit in progression-free survival (PFS) and has the potential to change clinical practice.

Transcript:

Another [study] that may change practice [is] a randomized phase 3 study of cabozantinib vs placebo that Marcia S. Brose, MD, PhD, of the Perelman School of Medicine at the University of Pennsylvania, presented as part of the head neck oral session. That was also a positive study. It was only in patients who had prior VEGF TKIs. It was either in the second- or third-line [setting]. Patients [had to have] either [prior] sorafenib [Nexavar], lenvatinib [Lenvima] or both...and shown progression. [This trial] also showed a gigantic progression-free survival [benefit]; it was so big that the study was stopped early. There are a lot of questions still. We do not know what the true median PFS was because most patients were censored even before 9 months. The study reported early and we do not know what the mature data show.

Reference

Brose MS, Robinson , Sherman SI, et al. Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: results from the phase 3 COSMIC-311 trial. J Clin Oncol. 2021;39(suppl 15):6001. doi:10.1200/JCO.2021.39.15_suppl.6001

Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Related Content